The objective of this study was to explore whether BM-MSCs may be used as a NK4 carrier for human pancreatic cancer treatment––a possibility that would require an experimental basis for the clinical application of manipulations of the NK4 gene product. This evidence concerns the gene IL32 and familial pancreatic carcinoma.